ClinicalTrials.gg
TerminatedNCT00408148Updated Dec 10, 2010

High Density Lipoprotein Turnover

A Phase 3 interventional study of Placebo and Rimonabant in Obesity, sponsored by Sanofi. Terminated at 4 sites in 4 countries. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-12-10.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision has been taken in light of recent demands by certain national health authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing rimonabant in Obesity — none open to participants now, none under way, none of them phase 3. Rimonabant · Obesity.

Enrollment
19th of 21
64 · median 643
Started
2006
with 3 others
Phase 3
18 of 21
none open now
Registered
10th of 21
by date
Lead sponsor
19 of 21
Sanofi

Among the 21 studies testing rimonabant in Obesity, this one is the 19th largest by enrollment, is one of 4 that started in 2006, is one of 18 in phase 3, and was the 10th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 21 studies testing rimonabant in Obesity is open now. The open studies under Obesity, anywhere →

About rimonabant

Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing rimonabant in Obesity as a file.
02

Study summary

The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.

Primary objectives:

  • To assess effect of Rimonabant on HDL ApoA-I fractional catabolic rate (FCR).

Secondary objectives:

  • To assess effect of Rimonabant on HDL ApoA-I production rate (PR) and on other lipoprotein kinetics.
  • To assess effect of Rimonabant on lipids, glycemic and inflammatory parameters
  • To assess effect of Rimonabant on body composition
  • To assess safety of Rimonabant
03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Abdominally obese patients with additional cardiometabolic risk factors
  • Females must be
  • > 27 kg/m² and \< 40 kg/m²
  • Men or women with abdominal obesity according to NCEP/ATPIII criteria: Waist Circumference > 88 cm in women; > 102 cm in men
  • With at least one lipid abnormality defined as:
  • Fasting Triglycerides level > 1.7 mmol/L (150 mg/dL) and \< 4.5 mmol/L (400 mg/dL)
  • HDL \< 1.03 mmol/L (40 mg/dL) in men and \< 1.29 mmol/L (50 mg/dL) in women

Exclusion criteria

Exclusion Criteria:

  • HDL ≤ 0.60 mmol/L (23 mg/dl)
  • Plasma LDL-Cholesterol > 155 mg/dl (4.00 mmol/L) or total cholesterol 250 mg/dl (> 6.5mmol/L) or genetic hyperlipidaemia
  • Fasting triglycerides > 400 mg/dL (4.5 mmol/L)
  • Known heterozygous or homozygous familial hypercholesterolaemia or know type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia)
  • ApoE2/E2 homozygosity, Apo E4/E4 homozygosity
  • Type 2 diabetes treated with oral agents and/or insulin
  • Diet treated type 2 diabetic patients with ≥ 7%
  • History of cardio vascular disease
  • Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg.
  • Very low-calorie diet (1200 calories a day or less) or history of surgical procedures for weight loss (e.g., stomach stapling, bypass)
  • Body weight fluctuation > 5 Kg during the previous 3 months
  • History of bulimia or anorexia nervosa by criteria
  • Presence of any endocrine disease according to the investigator, Cushing syndrome, obesity secondary to hypothalamic/pituitary disorder.
  • Abnormal TSH and free T4 at baseline (Patients treated with thyroid replacement therapy must be on fixed and stable dose for at least 3 months prior to screening and must be in euthyroïd status.)
  • Severe hepatic impairment known by the investigator or or ALT > 3 times the at screening.
  • Known severe renal dysfunction ( \< 30 ml/min) or urine analysis (performed at screening by dipstick) showing 2+ or more protein
  • Presence of any condition (medical, including clinically significant abnormal laboratory test, psychological, social or geographical) actual or anticipated that the investigator feels would compromise the patient safety or limit his/her successful participation to the study
  • Patient treated for epilepsy
  • Ongoing major depressive illness
  • Uncontrolled psychiatric illness
  • History of alcohol and/or drug abuse
  • Smoker or smoking cessation within the past 3 months
  • Marijuana or hashish users
  • Previous participation in a Rimonabant study or to any other clinical trial within 4 weeks to study start
  • /intolerance to the active substance or to any of the such as lactose
  • Blood donation within the past 3 months prior to the study or planned during the study or within the 3 months from the study completing
  • Recent history of active peptic ulcer
  • Willebrand disease or other hemorrhagic diatheses
  • Administration of any of the following within 3 months prior to screening visit and susceptible to be prescribed during the study treatment period:
  • Lipid-lowering drugs intake
  • Anti obesity drugs
  • Other drugs for weight reduction (phentermine, amphetamines)
  • Herbal preparations for weight reduction
  • Other drugs known to affect lipid metabolism: retinoids, antiretroviral, estrogens and hormone replacement therapy, cyclosporine, glitazones, benfluorex, fish oils, plant sterols.
  • Thiazids (including fixed combination) at daily dose higher than 12.5 mg
  • Unselective beta-blockers
  • Prolonged use (more than one week) of systemic , neuroleptics
  • Anticoagulants
  • Ongoing antidepressive treatment

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Placebo comparator
    2

    Administration of one rimonabant placebo tablet once daily in the morning

    Drug: Placebo

  • Experimental
    1

    Administration of one tablet containing 20 mg of active rimonabant once daily in the morning

    Drug: Rimonabant

Interventions

  • DrugPlacebo

    Undistinguishable placebo tablets

  • White film-coated, for oral administration containing 20 mg of active rimonabant

06

What researchers measure

Primary outcomes

  1. The fractional catabolic rate (FCR) of HDL ApoA-I

    Time frame: After 12 months of treatment.

Secondary outcomes

  1. Production Rate (PR) of HDL ApoA-I and A-II, (FCR) of HDL ApoA-II

    Time frame: All across the study

  2. PR and FCR of VLDL1 and VLDL2 Apo B, VLDL1 and VLDL2 TG, IDL Apo B and LDL Apo B

    Time frame: All across the study

  3. Variation in ApoA-I, ApoA-II, Lp-AI, Lp-AII, pre-beta-HDL HDL2a, HDL2b, HDL3a, HDL3b, HDL3c, Apo B, Apo C III, TG, LDL-C, HDL-C levels

    Time frame: All across the study

  4. Variation in Glucose, insulin, HbA1c, leptin, adiponectin

    Time frame: All across the study

  5. Variation in hs-CRP, TNF-alpha, CETP, PLTP and LCAT activities, lipoprotein and hepatic lipase activities in post-heparin plasma

    Time frame: All across the study

  6. Variation in whole body fat

    Time frame: All across the study

  7. Variation in abdominal sub-cutaneous and visceral fat

    Time frame: All across the study

  8. Variation in liver fat

    Time frame: All across the study

  9. Variation in blood pressure

    Time frame: All across the study

  10. Variation in body weight, waist circumference, waist/hip ratio

    Time frame: From the beginning to the end of the study

  11. CE/TG ratio in HDL

    Time frame: All across the study

  12. Adverse events

    Time frame: From the beginning to the end of the study

07

Study locations

4 sites
  • Sanofi-Aventis Administrative Office
    North Ryde, Australia
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Guildford, United Kingdom
08

References and documents

Publications

  • Verges B, Adiels M, Boren J, Barrett PH, Watts GF, Chan D, Duvillard L, Soderlund S, Matikainen N, Kahri J, Robin I, Taskinen MR. Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study. J Clin Endocrinol Metab. 2014 Nov;99(11):4281-90. doi: 10.1210/jc.2014-2365. Epub 2014 Jul 31. PubMed 25077901 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2006
First posted
Dec 6, 2006
Start
Oct 2006
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Last update
Dec 10, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00408148
Lead sponsor
Sanofi
First posted
Dec 6, 2006
Start date
Oct 2006
Primary completion
Dec 2008
Completion
Dec 2008
Last update
Dec 10, 2010

Study contacts

Valérie Pilorget
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion